Bayer, Schering Thai units merge (Thailand)
This article was originally published in PharmAsia News
Executive Summary
Bayer Thai Co Ltd and Schering (Bangkok) Ltd are operating under a new name, Bayer Schering Pharma, following the merger of their multinational parent companies. The new division under Bayer Thai Co Ltd continues to focus on research and distribution of pharmaceutical products and aims to be the leading pharmaceutical specialist in Thailand. Bayer Schering Pharma concentrates on women's health care, primary care, diagnostic imaging, and specialty care. The company is currently ranked number eight among multinational pharmaceutical companies in Thailand, and 11th in the overall Thai pharmaceutical market. Bayer Schering expects sales to grow by double digits this year and in the year to come. ''Bayer Schering Pharma is not only committed to continuing to market our current product range that has made us so strong, but to also further expand our portfolio. However, our prime objective is not to be the number one in size; we are instead aiming at leading positions in selected therapeutic areas,'' said Uwe Dalichow, general manager of Bayer Shering Pharma. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.